HIK.L vs JAZZ
HIK.L: Hikma Pharmaceuticals is a global provider of generic, branded, and injectable medicines with a significant footprint in the US and MENA markets. JAZZ: Jazz Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for patients with complex sleep disorders and challenging oncology conditions.
Side-by-side fundamentals
| Metric | HIK.L | JAZZ | Edge |
|---|---|---|---|
| Price as of 2026-08-20 close | £16.24 | $254.28 | |
| Market cap | $4.7B | $16.5B | |
| P/E as of 2026-08-24 | n/a | 16.97 | |
| PEG as of 2026-08-24 | n/a | 65.11 | |
| Net margin | +12.2% | +20.4% | JAZZ higher |
| Gross margin | +43.0% | +88.4% | JAZZ higher |
| Operating margin as of 2026-08-24 | n/a | +19.5% | |
| ROE | +15.6% | +21.4% | JAZZ higher |
| ROA as of 2026-08-24 | n/a | +8.2% | |
| Debt / equity as of 2026-08-24 | n/a | 0.91 | |
| Revenue growth (YoY) as of 2026-08-24 | n/a | +12.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +5.3% | |
| Beta as of 2026-08-24 | n/a | 0.37 | |
| 1-year return as of 2026-08-20 close | -10.3% | +111.0% | JAZZ higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.